iSCORE-PD: an isogenic stem cell collection to research Parkinson’s Disease
Oriol Busquets,Hanqin Li,Khaja Mohieddin Syed,Pilar Alvarez Jerez,Jesse Dunnack,Riana Lo Bu,Yogendra Verma,Gabriella R. Pangilinan,Annika Martin,Jannes Straub,YuXin Du,Vivien M. Simon,Steven Poser,Zipporiah Bush,Jessica Diaz,Atehsa Sahagun,Jianpu Gao,Dena G. Hernandez,Kristin S. Levine,Ezgi O. Booth,Helen S. Bateup,Donald C. Rio,Dirk Hockemeyer,Cornelis Blauwendraat,Frank Soldner
DOI: https://doi.org/10.1101/2024.02.12.579917
2024-02-13
Abstract:Parkinson’s disease (PD) is a neurodegenerative disorder caused by complex genetic and environmental factors. Genome-edited human pluripotent stem cells (hPSCs) offer the uniique potential to advance our understanding of PD etiology by providing disease-relevant cell-types carrying patient mutations along with isogenic control cells. To facilitate this experimental approach, we generated a collection of 55 cell lines genetically engineered to harbor mutations in genes associated with monogenic PD ( A53T, A30P, Ex3del, Q129X, Ex1-5del, G2019S, FS, R498X/FS, c.801 A>G+FS, R258Q/FS, A444P, W395C, IVS2+1). All mutations were generated in a fully characterized and sequenced female human embryonic stem cell (hESC) line (WIBR3; NIH approval number NIHhESC-10-0079) using CRISPR/Cas9 or prime editing-based approaches. We implemented rigorous quality controls, including high density genotyping to detect structural variants and confirm the genomic integrity of each cell line. This systematic approach ensures the high quality of our stem cell collection, highlights differences between conventional CRISPR/Cas9 and prime editing and provides a roadmap for how to generate gene-edited hPSCs collections at scale in an academic setting. We expect that our isogenic stem cell collection will become an accessible platform for the study of PD, which can be used by investigators to understand the molecular pathophysiology of PD in a human cellular setting.
Neuroscience